Finch Therapeutics’ CP101 Receives FDA’s Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection

 Finch Therapeutics’ CP101 Receives FDA’s Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection

Finch Therapeutics’ CP101 Receives FDA’s Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection

Shots:

  • The FDA’s BT designation follows P-II PRISM3 study results assessing CP101 vs PBO in patients with recurrent C. difficile
  • FDA’s BT designation is granted to the drugs showing clinical improvement over currently available therapy in serious or life-threatening conditions on at least one clinically significant endpoint with benefits of Priority Review and accelerated approval
  • CP101 is an oral, qd, drug developed using Finch’s Full-Spectrum Microbiota (FSM) platform, targeted for prevention of recurrent C. difficile infections

Click here to read full press release/ article | Ref: Business Wire  | Image: Finch Therapeutics

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post